secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-002932
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon appoints Dr. Rick Artis as Chief Scientific Officer, succeeding Dr. Larry Mattheakis
--------------------------------------------------------------------------------

- Dean 'Rick' Artis, Ph.D., appointed CSO effective January 6, 2023, succeeding Larry C. Mattheakis who is departing.
- Artis previously served as SVP of Chemistry at Annexon and discovered small molecule ANX1502.
- Artis most recently was CSO at Octant Bio and has discovery-to-clinic experience across multiple therapeutic areas.
- He will lead all research efforts with focus on expanding small molecule pipeline and advancing complement portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/0001193125-23-002932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/d426219d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer